Edith A. Perez

59.0k total citations · 11 hit papers
400 papers, 30.1k citations indexed

About

Edith A. Perez is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Edith A. Perez has authored 400 papers receiving a total of 30.1k indexed citations (citations by other indexed papers that have themselves been cited), including 311 papers in Oncology, 176 papers in Cancer Research and 104 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Edith A. Perez's work include Cancer Treatment and Pharmacology (166 papers), Breast Cancer Treatment Studies (157 papers) and HER2/EGFR in Cancer Research (153 papers). Edith A. Perez is often cited by papers focused on Cancer Treatment and Pharmacology (166 papers), Breast Cancer Treatment Studies (157 papers) and HER2/EGFR in Cancer Research (153 papers). Edith A. Perez collaborates with scholars based in United States, Canada and Belgium. Edith A. Perez's co-authors include Nancy E. Davidson, Silvana Martino, James N. Ingle, Julie R. Gralow, Molin Wang, Antonio C. Wolff, Robert B. Jenkins, George W. Sledge, Kathy D. Miller and Maura N. Dickler and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nucleic Acids Research.

In The Last Decade

Edith A. Perez

394 papers receiving 29.2k citations

Hit Papers

Recommendations for Human Epidermal Growt... 1999 2026 2008 2017 2013 2007 2013 2014 2005 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
    2013 3.1k citations Antonio C. Wolff, Robert B. Jenkins et al. Journal of Clinical Oncology profile →
  2. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
    2007 2.3k citations Molin Wang, Julie R. Gralow et al. profile →
  3. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
    2013 1.3k citations Antonio C. Wolff, Robert B. Jenkins et al. profile →
  4. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
    2014 953 citations Sylvia Adams, Robert J. Gray et al. Journal of Clinical Oncology profile →
  5. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
    2005 818 citations James N. Ingle, Silvana Martino et al. JNCI Journal of the National Cancer Institute profile →
  6. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
    2011 766 citations Edith A. Perez et al. Journal of Clinical Oncology profile →
  7. Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
    2008 672 citations Joseph A. Sparano, Molin Wang et al. profile →
  8. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
    2014 671 citations Edith A. Perez, Edward H. Romond et al. Journal of Clinical Oncology profile →
  9. Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes
    2005 567 citations Vera J. Suman, Daniel W. Visscher et al. Journal of Clinical Oncology profile →
  10. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
    2006 518 citations Lori J. Goldstein, Silvana Martino et al. profile →
  11. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
    1999 483 citations Edith A. Perez et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edith A. Perez United States 79 20.7k 11.1k 6.6k 5.8k 4.4k 400 30.1k
Steven Shak United States 54 16.7k 0.8× 11.2k 1.0× 8.1k 1.2× 5.6k 1.0× 3.1k 0.7× 133 28.1k
Jonas Bergh Sweden 73 15.6k 0.8× 11.6k 1.0× 11.2k 1.7× 4.9k 0.9× 3.3k 0.8× 521 29.1k
Kathleen I. Pritchard Canada 72 15.6k 0.7× 9.9k 0.9× 6.1k 0.9× 5.4k 0.9× 5.0k 1.1× 369 25.4k
Louis Fehrenbacher United States 63 25.3k 1.2× 8.0k 0.7× 8.9k 1.4× 10.2k 1.8× 2.7k 0.6× 157 35.9k
Antonio C. Wolff United States 71 15.9k 0.8× 10.7k 1.0× 5.5k 0.8× 4.9k 0.8× 1.9k 0.4× 360 24.8k
Karen A. Gelmon Canada 73 15.9k 0.8× 7.0k 0.6× 5.6k 0.9× 6.6k 1.1× 2.6k 0.6× 393 23.8k
Vicente Valero United States 94 17.3k 0.8× 13.2k 1.2× 5.4k 0.8× 4.9k 0.8× 2.2k 0.5× 500 27.9k
George W. Sledge United States 72 14.8k 0.7× 9.6k 0.9× 7.5k 1.1× 6.3k 1.1× 1.7k 0.4× 444 25.4k
Martine Piccart Belgium 102 27.4k 1.3× 16.4k 1.5× 12.8k 2.0× 9.2k 1.6× 4.9k 1.1× 836 42.9k
James N. Ingle United States 74 13.9k 0.7× 9.4k 0.8× 5.6k 0.9× 4.0k 0.7× 7.9k 1.8× 365 23.6k

Countries citing papers authored by Edith A. Perez

Since Specialization
Citations

This map shows the geographic impact of Edith A. Perez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edith A. Perez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edith A. Perez more than expected).

Fields of papers citing papers by Edith A. Perez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edith A. Perez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edith A. Perez. The network helps show where Edith A. Perez may publish in the future.

Co-authorship network of co-authors of Edith A. Perez

This figure shows the co-authorship network connecting the top 25 collaborators of Edith A. Perez. A scholar is included among the top collaborators of Edith A. Perez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edith A. Perez. Edith A. Perez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chumsri, Saranya, Zhuo Li, Alvaro Moreno‐Aspitia, et al.. (2024). Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor–Positive, HER2-Positive Breast Cancer. Journal of the National Comprehensive Cancer Network. 22(7). 463–468.
2.
Jaeckle, Kurt A., Jesse G. Dixon, Alvaro Moreno‐Aspitia, et al.. (2020). Intra‐CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases. Cancer Medicine. 9(21). 7935–7942. 21 indexed citations
3.
4.
Norton, Nadine, Kathleen Tenner, Karla V. Ballman, et al.. (2018). Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. Breast Cancer Research. 20(1). 52–52. 11 indexed citations
5.
6.
Perez, Edith A., Karla V. Ballman, Afshin Mashadi-Hossein, et al.. (2016). Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial. JNCI Journal of the National Cancer Institute. 109(2). djw207–djw207. 27 indexed citations
7.
Borgés, Sahra, Edith A. Perez, E. Aubrey Thompson, et al.. (2015). Effective Targeting of Estrogen Receptor–Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101. Molecular Cancer Therapeutics. 14(6). 1306–1316. 51 indexed citations
8.
Perez, Edith A., Edward H. Romond, Vera J. Suman, et al.. (2014). Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology. 32(33). 3744–3752. 671 indexed citations breakdown →
9.
Ballman, Karla V., Maria Vassilakopoulou, Amylou C. Dueck, et al.. (2014). EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. British Journal of Cancer. 111(6). 1065–1071. 23 indexed citations
10.
Adams, Sylvia, Robert J. Gray, Sandra Demaria, et al.. (2014). Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology. 32(27). 2959–2966. 953 indexed citations breakdown →
11.
Giordano, Sharon H., Sarah Temin, Jeffrey J. Kirshner, et al.. (2014). Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 32(19). 2078–2099. 258 indexed citations
12.
Mahoney, Douglas W., Terry M. Therneau, S. Keith Anderson, et al.. (2013). Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples. BMC Research Notes. 6(1). 33–33. 9 indexed citations
13.
Norton, Nadine & Edith A. Perez. (2013). How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?. Breast Cancer Research. 15(1). 101–101. 3 indexed citations
14.
Asmann, Yan W., Brian M. Necela, Krishna R. Kalari, et al.. (2012). Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer. Cancer Research. 72(8). 1921–1928. 75 indexed citations
15.
Cooper, Simon, Christina A. Von Roemeling, Laura A. Marlow, et al.. (2012). Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers. Molecular Cancer Therapeutics. 11(10). 2105–2115. 52 indexed citations
16.
Reinholz, Monica M., Kathleen Tenner, David W. Hillman, et al.. (2011). Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437. Clinical Cancer Research. 17(22). 7183–7193. 45 indexed citations
17.
Perez, Edith A., Monica M. Reinholz, David W. Hillman, et al.. (2010). HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology. 28(28). 4307–4315. 176 indexed citations
18.
Reinholz, Monica M., Jeanette E. Eckel‐Passow, S. Keith Anderson, et al.. (2010). Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL®platform. BMC Medical Genomics. 3(1). 60–60. 11 indexed citations
19.
Halyard, Michele Y., Thomas M. Pisansky, Amylou C. Dueck, et al.. (2009). Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831. Journal of Clinical Oncology. 27(16). 2638–2644. 127 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven Shak Breakdown of academic impact, for papers by Jonas Bergh Breakdown of academic impact, for papers by Kathleen I. Pritchard Breakdown of academic impact, for papers by Louis Fehrenbacher Breakdown of academic impact, for papers by Antonio C. Wolff Breakdown of academic impact, for papers by Karen A. Gelmon Breakdown of academic impact, for papers by Vicente Valero Breakdown of academic impact, for papers by George W. Sledge Breakdown of academic impact, for papers by Martine Piccart Breakdown of academic impact, for papers by James N. Ingle
Rankless by CCL
2026